Related Experiment Video
Updated: Jun 26, 2026
14:20
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Molecule-targeted agents in endometrial cancer
Angelo Delmonte1, Cristiana Sessa
1Oncology Institute of Southern Switzerland, Ospedale S Giovanni, Bellinzona, Switzerland.
Current Opinion in Oncology
|December 25, 2008
Summary
Targeted therapies show promise for endometrial cancer by addressing specific molecular alterations. Combining these agents may improve outcomes, with biomarkers aiding patient selection for better treatment response.
Area of Science:
- Gynecologic Oncology
- Molecular Biology
- Pharmacology
Background:
- Endometrial cancer is a common gynecologic malignancy often treated with toxic platinum-based and anthracycline combinations.
- Emerging research in molecular biology suggests targeted agents could improve clinical outcomes for endometrial cancer patients.
- Understanding the molecular landscape of endometrial cancer is crucial for developing more effective treatments.
Purpose of the Study:
- To review the current understanding of molecular subtypes of endometrial cancer.
- To explore the potential of molecule-targeted agents in treating endometrial cancer.
- To evaluate the rationale and preliminary results of targeted therapies in endometrial cancer.
Main Methods:
- Review of preclinical and clinical data on targeted agents for endometrial cancer.
- Analysis of molecular alterations, including PTEN mutations and HER2/neu overexpression.
- Examination of Phase II study results for mTOR inhibitors and trastuzumab.
Main Results:
- Endometrial cancer comprises type I and type II, with distinct genetic profiles.
- Type I is associated with PTEN mutations leading to mTOR pathway hyperactivation.
- Type II frequently exhibits HER2/neu overexpression, driving tumor proliferation.
Conclusions:
- While single-agent targeted therapy shows limited antitumour activity, combination regimens are promising.
- Pharmacological rationale supports further evaluation of targeted therapies in endometrial cancer.
- Biomarker identification is essential for selecting patients likely to respond to targeted treatments.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...